The diffuse large B-cell lymphoma disease profile at Charlotte Maxeke Johannesburg Academic Hospital from July 2020 to June 2022

View Full Paper

Ask AI

Bookmark

Overall survival for patients with diffuse large B-cell lymphoma was 78.2% at year one and 53.1% by year three.
Among those with HIV, survival rates were 78.3% at year one and dropped to 51.6% by year three post-treatment.
Most patients, 74.1%, received R-CHOP as first-line therapy, indicating its common use in treatment.
The study revealed that DLBCL predominantly affects a younger population group in a high HIV burden setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis highlights survival outcomes in diffuse large B-cell lymphoma patients with HIV.

Tshole et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark